Novel seizure outcomes in patients with Lennox‐Gastaut syndrome: Post hoc analysis of seizure‐free days in rufinamide Study 303

OBJECTIVE: Drug development for patients with Lennox‐Gastaut syndrome (LGS) is based on clinical trials that use drop seizure counts. However, such counts do not assess total seizure burden and affect a patient's quality of life (QoL). In this post hoc analysis, we evaluated two novel seizure e...

Descripción completa

Detalles Bibliográficos
Autores principales: Auvin, Stéphane, Williams, Betsy, McMurray, Rob, Kumar, Dinesh, Perdomo, Carlos, Malhotra, Manoj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Full‐length Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546073/
https://www.ncbi.nlm.nih.gov/pubmed/31168494
http://dx.doi.org/10.1002/epi4.12314

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546073/
https://www.ncbi.nlm.nih.gov/pubmed/31168494
http://dx.doi.org/10.1002/epi4.12314

Ejemplares similares